Preoperative Preradiotherapy TTFields

Inclusion Criteria13

• Patient is aged >35 years (age range of more likely to suffer from an IDHwt World Health Organisation (WHO) grade 4 astrocytoma)*
• Patient is male or female.
• Patient has a new radiological diagnosis of glioblastoma.
• Patient has a performance status judged by WHO, Eastern Cooperative Oncology Group (ECOG) score = 0-1.
• Patient has been reviewed by Neuro-oncology multidisciplinary team (MDT - neurosurgeon, clinical oncologist, radiologist and pathologist); MDT consensus that offering study entry is clinically appropriate and safe i.e. patient unlikely to come to harm (e.g. hydrocephalus) from delayed surgery and pre-operative Optune based on available clinical information and imaging.
• PI has confirmed at the first clinic visit that study entry is clinically appropriate and safe (e.g. lack of severe and debilitating symptoms of raised intracranial pressure).
• There is intention to treat the patient with surgical resection and postoperative adjuvant therapy as per current standard of care (40Gy/15 fr or 60Gy/30fr).
• Patient has adequate haematological and biochemical parameters for surgery and contrast agent administration (full blood count and coagulation profile deemed acceptable by clinical team, eGFR >30ml/min).
• Patient has mental capacity to consent for treatment.
• Patient is able and willing to give informed consent
• Criteria specific to the experimental arm:
• Patient is able and willing to comply with study protocol requirements to continuously shave their head
• Patient is able and willing to comply with study protocol requirements to wear Optune equipment for the required duration.